BIOR vs. LPCN, UBX, FBRX, ITRM, ACST, ONCT, APRE, QLI, LUMO, and ENLV
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Lipocine (LPCN), Unity Biotechnology (UBX), Forte Biosciences (FBRX), Iterum Therapeutics (ITRM), Acasti Pharma (ACST), Oncternal Therapeutics (ONCT), Aprea Therapeutics (APRE), Qilian International Holding Group (QLI), Lumos Pharma (LUMO), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Lipocine (NASDAQ:LPCN) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Lipocine's return on equity of 0.00% beat Biora Therapeutics' return on equity.
Lipocine received 339 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 70.29% of users gave Lipocine an outperform vote while only 66.67% of users gave Biora Therapeutics an outperform vote.
Lipocine has higher earnings, but lower revenue than Biora Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lipocine and Lipocine both had 3 articles in the media. Biora Therapeutics' average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.
Lipocine has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are owned by institutional investors. 6.1% of Lipocine shares are owned by company insiders. Comparatively, 23.2% of Biora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Biora Therapeutics beats Lipocine on 8 of the 13 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
